Protein Therapies

Innovative polypeptide drugs engineered from naturally occurring domains and scaffolds

BioNTech Protein Therapies GmbH has two key protein therapy platforms: bispecific antibodies and nanoparticles. Bispecific antibodies make it possible to address two disease-relevant targets within one molecule. In oncology indications, for example, this approach can engage an immune-system cell and at the same time bind to a specific surface marker on the cancer cell thus helping the immune cell to recognize and destroy the cancer.

Our nanoparticles include our Microbody®-Technology that has antibody-like binding capabilities with fewer of the constraints related to very large biologic molecules. We also developed the SAPHIR®-Platform, highly immunogenic self-assembling nanoparticles that can induce a very specific and potent human immune response for use in cancer and vaccines.

Protein Therapies Platforms

  • Bispecific Antibodies
    • Superior efficacy to conventional antibodies
    • Retargeting of cytotoxic T cells to kill tumor cells
    • Versatile platform technology to match diverse requirements

  • Microbody® Technology
    • Scaffold-based binding proteins based on knottins
    • Phage display based discovery platform
    • Highly cost-effective production (using solid-phase peptide synthesis)
    • Enhanced tumor penetration due to small size
    • In vivo tumor imaging and targeted drug delivery
    • Applications in therapeutics and diagnostics field

  • SAPHIR®
    • Highly immunogenic, self-assembling nanoparticles
    • Induction of very potent and specific antibodies and cellular immune responses
    • Cost-effective to manufacture and stable at room temperature